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The emergence of drug-resistant bacteria poses a serious threat to human health. In the case of several antibiotics,
including those of the quinolone and rifamycin classes, bacteria rapidly acquire resistance through mutation of
chromosomal genes during therapy. In this work, we show that preventing induction of the SOS response by
interfering with the activity of the protease LexA renders pathogenic Escherichia coli unable to evolve resistance in vivo
to ciprofloxacin or rifampicin, important quinolone and rifamycin antibiotics. We show in vitro that LexA cleavage is
induced during RecBC-mediated repair of ciprofloxacin-mediated DNA damage and that this results in the
derepression of the SOS-regulated polymerases Pol II, Pol IV and Pol V, which collaborate to induce resistance-
conferring mutations. Our findings indicate that the inhibition of mutation could serve as a novel therapeutic strategy
to combat the evolution of antibiotic resistance.
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Introduction
The worldwide emergence of antibiotic-resistant bacteria
threatens to undo the dramatic advances in human health
that were ushered in with the discovery of these drugs in the
mid-1900s. Today, resistance has rendered most of the
original antibiotics obsolete for many infections, mandating
an increased reliance on synthetic drugs. However, bacteria
also evolve resistance to these drugs, typically by acquiring
chromosomal mutations [1–6]. Within the classical paradigm
that mutations are the inevitable consequence of replicating
a large genome with polymerases of ﬁnite ﬁdelity, resistance-
conferring mutations are unavoidable. However, recent
evidence suggests that bacteria may play a more active role
in the mutation of their own genomes in response to at least
some DNA-damaging agents by inducing proteins that
actually promote mutation [7–15]. If the acquisition of
antibiotic resistance-conferring mutations also requires the
induction of these proteins, then their inhibition would
represent a novel approach to combating the growing
problem of drug resistance.
In an initial effort to examine the role of induced mutation
in the evolution of antibiotic resistance, we have focused our
studies on the synthetic antibiotic ciproﬂoxacin. Ciproﬂox-
acin is a member of the quinolone family of antibiotics, which
is rapidly becoming the most important family of antibiotics
[16]. Quinolones function by interfering with the two
essential type II DNA topoisomerases in bacteria, gyrase
and topoisomerase IV [17]. These topoisomerases normally
function by forming a protein-bridged DNA double strand
break (DSB), manipulating DNA strand topology, and ﬁnally
rejoining the DNA ends. Ciproﬂoxacin reversibly binds to the
protein-bridged DSB intermediate and inhibits rejoining of
the DNA ends. The toxic effects of ciproﬂoxacin may be the
result of topoisomerase subunit dissociation without re-
ligation of the DNA ends [17,18], likely producing free double
strand ends (DSEs) when the protein-DNA bond is eventually
hydrolyzed or the DNA is processed by a nuclease. In
addition, covalently bound topoisomerases may also block
DNA replication forks, which after processing will also
produce DSEs [17,19–23]. Resistance to ciproﬂoxacin requires
mutations in the genes that encode the topoisomerases (gyrA
and gyrB, encoding gyrase, and parC and parE, encoding
topoisomerase IV) or in the genes that affect cell permeability
or drug export [1,17].
To understand how mutation could be induced by
ciproﬂoxacin, it is essential to consider how bacteria respond
to the presence of the antibiotic. Previously it was suggested
that ciproﬂoxacin-mediated DNA damage may be repaired by
nucleotide excision repair (NER) or homologous recombina-
tion (HR) [17]. RecA-single-stranded DNA (ssDNA) ﬁlaments
play an important role in these processes by catalyzing strand
invasion of a DNA end into a homologous sequence.
However, RecA-ssDNA ﬁlaments also play an important role
in induced mutation by binding the SOS [10] gene repressor
LexA and unmasking its autoproteolytic activity [24]. Upon
autoproteolysis, LexA no longer represses the approximately
30 genes whose protein products facilitate the repair of DNA
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particular, sufﬁcient reduction of the cellular concentration
of LexA repressor results in the transcription of the genes
encoding Pol II (polB), Pol IV (dinB), and Pol V (umuD and
umuC), which are three nonessential DNA polymerases that
have been shown to be required for mutation in response to
DNA damage [10,25–28].
Because ciproﬂoxacin may induce repair pathways that
involve RecA-ssDNA ﬁlament formation, the drug itself may
act to induce the mutations that confer resistance. This
hypothesis is consistent with observations that quinolones
can be mutagenic and can induce the SOS response [17].
Here, using an in vivo infection model, we show that
interfering with LexA autoproteolysis renders pathogenic
Escherichia coli unable to mutate and acquire resistance to
ciproﬂoxacin. The same result is demonstrated in vivo for the
antibiotic rifampicin, which is a semisynthetic member of the
rifamycin class of antibiotics that inhibits the bacterial RNA
polymerase. The in vivo results are recapitulated in vitro for
ciproﬂoxacin (here, we use in vitro to refer to bacteria in
liquid cultures or on solid media). To understand how LexA
cleavage is induced by ciproﬂoxacin and how this cleavage
mediates resistance, we examined the contribution of a
variety of different genes to ciproﬂoxacin tolerance and
resistance in vitro. We show that E. coli repairs ciproﬂoxacin-
induced DNA damage primarily by RecBC-dependent HR,
and to a lesser extent by illegitimate recombination (IR).
Finally, we show that Pol II, Pol IV, and Pol V are all required
for the evolution of resistance.
Results
LexA Cleavage Is Required for the Evolution of Resistance
to Ciprofloxacin and Rifampicin In Vivo
To test whether activation of the SOS response is required
to induce the mutations that confer ciproﬂoxacin resistance
during therapy, we used a neutropenic murine thigh
infection model [29] and the pathogenic E. coli strain ATCC
25922. Mice were infected with 10
6 colony-forming units (cfu)
of either the DlacZ (control) or lexA(S119A) 25922 strain
(Table 1). The LexA(S119A) mutant cannot undergo auto-
proteolysis and thus renders bacteria unable to de-repress the
SOS genes [30]. After infection, ciproﬂoxacin (0.5 mg/kg) was
administered every 12 h. After 24, 48, and 72 h, mice were
sacriﬁced, thigh tissue was homogenized, and dilutions of the
homogenate were plated on media with and without
ciproﬂoxacin to quantify the number of viable and resistant
cfu, respectively (Figure 1A). Treatment with ciproﬂoxacin
had the same, slow bactericidal effect on both strains,
reducing the total cfu/thigh approximately 250-fold over the
72 h of treatment. In mice infected with the DlacZ control
strain, signiﬁcant resistance emerged, amounting to approx-
imately 3% of the entire population by 72 h. Individual
clones were found to have ciproﬂoxacin minimum inhibitory
concentrations (MICs) as high as 640 ng/ml (ten clones
analyzed), signiﬁcantly increased from the 12 ng/ml MIC
observed for the DlacZ strain before infection. In dramatic
contrast, no resistant mutants were isolated from mice
infected with the lexA(S119A) strain. The MICs of the
lexA(S119A) clones recovered from the mouse thigh and
isolated from the ciproﬂoxacin-free media remained approx-
imately equal to that of the strain prior to infection
(approximately 12 ng/ml, ten clones analyzed).
We next used the same mouse model to characterize the
evolution of resistance to rifampicin in vivo. Again, mice
were infected with 10
6 cfu of either the DlacZ control or the
lexA(S119A) 25922 strain. Rifampicin (100 mg/kg) was admin-
istered every 12 h, mice were sacriﬁced after 24, 48, and 72 h,
and the total number of viable and rifampicin-resistant cfu
was determined. Treatment with rifampicin also had a slow
bactericidal effect on both strains (Figure 1B); however, by 72
h all of the DlacZ clones recovered from the thigh were
resistant to rifampicin. MICs of individual rifampicin-
resistant DlacZ clones were all higher than 250 lg/ml (ten
clones analyzed), which is substantially higher than the 8 lg/
ml MIC of the parent strain. Remarkably, despite the rapid
acquisition of resistance in the control strain, no resistant
clones were isolated from mice infected with the lexA(S119A)
strain. The MICs of the lexA(S119A) clones recovered from the
mouse thigh remained 8 lg/ml, approximately the same as the
parent strain (ten clones analyzed). We conclude that LexA
cleavage is absolutely required for the evolution of resistance
to both ciproﬂoxacin and rifampicin during therapy in vivo.
Ciprofloxacin Induces Biochemical Pathways That
Facilitate Mutation In Vitro
In order to further characterize the genetic requirements
of these resistance-conferring mutations, we studied bacteria
in vitro. We constructed an isogenic series of mutants in the
E. coli strain MG1655 (MG1655 is not pathogenic, but it has
been fully sequenced [31], which facilitated the construction
of the required deletion strains) (Table 1). As with the in vivo
studies, a DlacZ strain was constructed as a control (the DlacZ
strain exhibited wild-type growth and mutation). We ﬁrst
determined that the ciproﬂoxacin MIC for the DlacZ control
strain is 35 ng/ml in liquid media (Table 2). On solid media,
we found that 40 ng/ml ciproﬂoxacin killed 99% of the cells
within 24 h of plating, while the remaining 1% of the
population persisted for several weeks, allowing for the
characterization of the bacteria in the presence of the
antibiotic (Figure 2).
We measured the rate at which the DlacZ control strain
evolves resistance in vitro on solid media containing 40 ng/ml
ciproﬂoxacin; at this concentration, single mutations (typi-
cally in gyrA) are sufﬁcient to confer resistance (Tables 2 and
S1) [1]. DlacZ cells were grown in permissive liquid culture
and then plated onto ciproﬂoxacin-containing media. Re-
sistant colonies were counted as they arose, in 24 h intervals
over 14 d. Colonies that formed immediately (at or before day
2) were attributed to cells that had acquired resistance prior
to exposure to ciproﬂoxacin (via ‘‘pre-exposure’’ mutations),
while colonies that formed on day 3 or later were attributed
to cells that acquired resistance after exposure to ciproﬂox-
acin (via ‘‘post-exposure’’ mutations). Assignments of pre-
and post-exposure mutations were validated by using two
different reconstruction assays designed to conﬁrm when the
mutations occurred (see Materials and Methods). Mutation
rates were deﬁned as the number of resistant colonies that
arose per time, per viable cell (it should be noted that this
experiment detects only those mutations that confer resist-
ance). We observed a pre-exposure mutation rate of 9.0 (6
9.5) 3 10
10 mutants/viable cell/d, and a post-exposure
mutation rate of 1.8 (6 0.69) 3 10
5 mutants/viable cell/d
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Inhibition of Mutation(Table 3). Thus, ciproﬂoxacin induces resistance by a factor of
10
4. These rates are in agreement with those reported
previously by Hall using a similar in vitro assay [32].
We next examined the mutation spectrum of the gyrA gene
in the resistant clones by sequencing a 1,000-nt region
encompassing the quinolone resistance-determining region
[33]. We found that the spectrum of the post-exposure
mutations differed signiﬁcantly from the pre-exposure
mutations (Table 3). In the pre-exposure mutants (ten clones
sequenced) we observed strictly substitution mutations, while
in the post-exposure mutants (19 clones sequenced) we
observed both substitutions and a three-basepair, in-frame
deletion that removed the codon for Ser83. This ‘‘codon
deletion’’ occurred despite a lack of ﬂanking direct repeats or
palindromic sequences, which are often thought to facilitate
spontaneous deletions.
LexA Cleavage Is Required for the Acquisition of
Resistance In Vitro
To characterize the role of LexA cleavage and the SOS
response in the evolution of resistance in vitro, we con-
structed a lexA(S119A) MG1655 strain. Mutation of LexA did
not affect growth or persistence in the presence of 40 ng/ml
ciproﬂoxacin (Figure 2C and Table 2). Previously, another
noncleavable LexA mutant, lexA(G85D), was shown to be
moderately sensitive to high levels of ciproﬂoxacin (63 MIC)
[34,35]. The difference in sensitivities associated with these
two noncleavable LexA mutants is likely the result of
different levels of ciproﬂoxacin-mediated DNA damage, i.e.,
an increased reliance on the induction of SOS genes under
the more damaging conditions employed in the lexA(G85D)
study.
We observed the same in vitro pre-exposure mutation rate
and spectrum for the lexA(S119A) strain as we did for the
control strain (Table 3). However, the lexA(S119A) strain
exhibited a post-exposure mutation rate that was approx-
imately 100-fold lower than that observed for the DlacZ
control strain (Table 3). The decreased evolution of resistance
did not depend on the concentration of the antibiotic, as
virtually identical results were obtained with 60 ng/ml of
ciproﬂoxacin (unpublished data). Given the low mutation
rate, only three post-exposure ciproﬂoxacin-resistant lexA(-
S119A) mutants were isolated (from more than 10
11 bacteria
plated, overall), but all three acquired resistance by deletion
of the Ser83 codon and not by substitution mutation (Table
3). Similar results were observed in vitro with the DlacZ and
lexA(S119A) 25922 strains used in the in vivo studies, both in
terms of mutation rates (Figure S1) and mutation spectrum.
To ensure that the reduced ability to evolve resistance
observed with the lexA(S119A) strain was not simply because
these cells grew slowly with gyrase mutations, we examined
the lexA(S119A) gyrA double mutants (Figure S2 and Table 2).
Relative to the respective control strain, each double mutant
showed virtually identical growth in the absence of cipro-
ﬂoxacin, virtually identical persistence in the presence of
ciproﬂoxacin, and identical ciproﬂoxacin MICs. In all, the
data indicate that the decreased evolution of resistance in the
lexA mutant did not result from decreased persistence or the
inability to grow upon acquisition of a gyr mutation, but
rather from an inability to induce mutations.
The evolution of clinically signiﬁcant resistance requires
the stepwise accumulation of several mutations [1]. To test
whether LexA cleavage is required for these additional
mutations, we examined the in vitro evolution of resistance
to 650 ng/ml ciproﬂoxacin in DlacZ control and lexA(S119A)
MG1655 strains already containing the prototypical ‘‘ﬁrst
step’’ Ser83Leu mutation in gyrA that confers resistance to 40
ng/ml ciproﬂoxacin (strains RTC0114 and RTC0122; see
Table 1). The ‘‘second step’’ mutation rate was 1.9 (6 0.21)
3 10
4 mutants/viable cell/d in the control strain and 5.5 (6
4.9) 3 10
7 mutants/viable cell/d in the lexA(S119A) strain
(Figure S3). Assuming that the ﬁrst and second step mutations
Table 1. Strains Used in This Work
Strain
Name
Genotype Source
MG1655 F-, k-, ilvG-, rfb-50, rph-1 P. Schimmel
ATCC 25922 F-, k- ATCC
PS6275 MG1655, Dbio nadA::Tn10 cl857 D(cro-bioA) P. Schimmel
RTC0001 MG1655, DlacZ::Km
R This work
RTC0002 MG1655, DpolB::Km
R This work
RTC0003 MG1655, DpolB::Spec
R This work
RTC0004 MG1655, DdinB::Km
R This work
RTC0005 MG1655, DumuDC::Km
R This work
RTC0006 MG1655, DumuDC::Cm
R This work
RTC0007 MG1655, DpolB::Spec
R, DdinB::Km
R This work
RTC0008 MG1655, DpolB::Spec
R, DumuDC::Cm
R This work
RTC0009 MG1655, DdinB::Km
R, DumuDC::Cm
R This work
RTC0010 MG1655, DpolB::Spec
R, DdinB::Km
R,
DumuDC::Cm
R
This work
RTC0011 MG1655, lexA(S119A):Km
R This work
RTC0012 MG1655, DrecA::Km
R This work
RTC0013 MG1655, DrecB::Km
R This work
RTC0014 MG1655, DrecD::Km
R This work
RTC0016 MG1655, DrecG::Km
R This work
RTC0017 MG1655, DruvB::Km
R This work
RTC0018 MG1655, DruvC::Km
R This work
RTC0020 MG1655, DpriA::Km
R This work
RTC0051 MG1655, DrecF::Cm
R This work
RTC0025 MG1655, DrecO::Km
R This work
RTC0026 MG1655, DrecR::Km
R This work
RTC0027 MG1655, DuvrB::Km
R This work
RTC0021 ATCC 25922, DlacZ::Km
R This work
RTC0022 ATCC 25922, lexA(S119A):Km
R This work
RTC0110 MG1655, gyrA(S83L) This work
RTC0111 MG1655, gyrA(D85G) This work
RTC0112 MG1655, gyrA(D82N) This work
RTC0113 MG1655, gyrA(WT), ciprofloxacin-resistant This work
RTC0114 MG1655, DlacZ::Km
R, gyrA(S83L) This work
RTC0115 MG1655, DpolB::Km
R, gyrA(S83L) This work
RTC0116 MG1655, DdinB::Km
R, gyrA(S83L) This work
RTC0117 MG1655, DumuDC::Km
R, gyrA(S83L) This work
RTC0118 MG1655, DpolB::Spec
R, DdinB::Km
R, gyrA(S83L) This work
RTC0119 MG1655, DpolB::Spec
R, DumuDC::Cm
R, gyrA(S83L) This work
RTC0120 MG1655, DdinB::Km
R, DumuDC::Cm
R, gyrA(S83L) This work
RTC0121 MG1655, DpolB::Spec
R, DdinB::Km
R,
DumuDC::Cm
R, gyrA(S83L)
This work
RTC0122 MG1655, lexA(S119A):Km
R, gyrA(S83L) This work
RTC0123 MG1655, DrecD::Km
R, gyrA(S83L) This work
RTC0124 MG1655, DrecF::Cm
R, gyrA(S83L) This work
RTC0125 MG1655, DrecO::Km
R, gyrA(S83L) This work
RTC0126 MG1655, DrecR::Km
R, gyrA(S83L) This work
RTC0127 MG1655, DuvrB::Km
R, gyrA(S83L) This work
RTC0131 MG1655, DrecG::Km
R, gyrA(S83L) This work
RTC0132 MG1655, DruvB::Km
R, gyrA(S83L) This work
RTC0133 MG1655, DruvC::Km
R, gyrA(S83L) This work
DOI: 10.1371/journal.pbio.0030176.t001
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Inhibition of Mutationare independent, the LexA mutant strain evolves resistance to
650 ng/ml ciproﬂoxacin in vitro with a rate that is
approximately 10
4-fold lower than the control strain. Because
clinical resistance typically requires three to ﬁve independent
mutations [1], the data imply that in the absence of efﬁcient
LexA cleavage, E. coli would evolve clinical resistance at least
10
6-fold slower. These in vitro results fully recapitulate the in
vivo mouse model studies and demonstrate that LexA
cleavage-mediated derepression of one or more genes is
essential for the efﬁcient evolution of resistance.
RecBC-Mediated Homologous Recombination Likely
Induces LexA Cleavage in the Presence of Ciprofloxacin
To understand how the presence of ciproﬂoxacin leads to
LexA cleavage, we characterized a series of MG1655 strains
harboring deletions of genes involved in various DNA repair
pathways (Tables 1 and S2). We reasoned that a pathway
important for mediating ciproﬂoxacin-induced LexA cleav-
age would involve the formation of RecA-ssDNA ﬁlaments
and also would be induced by the drug. Because the
ciproﬂoxacin-topoisomerase complexes act to cross-link
DNA, repair may occur by NER, mediated by UvrA, UvrB,
and UvrC, followed by recombinational gap repair, mediated
by RecF, RecO, RecR, and RecA [36–39]. We tested whether
this classical cross-link repair pathway is induced by the
antibiotic by examining the sensitivity and the pre- and post-
exposure mutation rates for DuvrB, DrecF, DrecO, and DrecR
strains. No differences in sensitivity (see Figure 2A and Table
2) or mutation rate (Table 3) were observed compared to the
control strain, suggesting that NER and RecFOR-mediated
recombinational gap repair are not induced in the presence
of ciproﬂoxacin or required for the efﬁcient evolution of
resistance. A previous study of uvrB and recF deletion strains
suggested that they were more sensitive to nalidixic acid than
was the wild-type strain [37]. However, unlike the current
study, the previous study involved short incubations at high
drug concentrations. Thus, the different experimental con-
ditions are likely responsible for the different results.
Because topoisomerase dissociation from the DNA may
generate free DSBs, repair may occur by a combination of HR
and DNA replication in a process generally referred to as
recombination-dependent DNA replication (RDR) [40,41]. In
Figure 1. Survival and Mutation of E. coli Mutants In Vivo after Starting
Antibiotic Therapy
Survival and mutation of DlacZ and lexA(S119A) mutants of E. coli
ATCC 25922 in thighs of neutropenic mice at 24-h intervals after
starting therapy with (A) ciprofoxacin or (B) rifampicin. Open circles
and triangles correspond to the total cfu/thigh of the DlacZ and
lexA(S119A) strains, respectively. Solid circles and triangles represent
the number of drug-resistant DlacZ and lexA(S119A) cfu/thigh,
respectively.
DOI: 10.1371/journal.pbio.0030176.g001
Table 2. Growth and Ciprofloxacin Sensitivity of MG1655-Derived Strains
Relevant Genotype
a Doubling Time (min) Ciprofloxacin MIC (ng/ml)
gyrA gyrA(S83L) gyrA gyrA(S83D) gyrA(S83L)
Wild-type, MG1655 30.2 6 0.6 34.8 6 1.4 35 —
b 500
DlacZ 28.9 6 1.6 25.7 6 1.1 35 250 500
DpolB 30.6 6 1.4 32.8 6 2.5 30 250 400
DdinB 24.5 6 1.7 30.9 6 3.5 35 250 500
DumuDC 26.0 6 2.0 24.3 6 0.3 35 250 500
DpolB DdinB 24.7 6 4.4 35.2 6 5.1 30 250 500
DpolB DumuDC 31.5 6 2.4 36.7 6 0.2 30 250 500
DdinB DumuDC 36.8 6 3.8 32.5 6 5.0 35 250 500
DpolB DdinB DumuDC 28.1 6 1.4 30.7 6 1.9 30 250 500
lexA(S119A) 30.0 6 2.3 28.1 6 3.5 30 250 350
DrecD 32.5 6 0.5 33.2 6 2.3 30 —
b 350
DrecF 39.1 6 6.1 40.0 6 5.8 40 —
b 400
DrecO 33.8 6 2.4 35.0 6 4.7 35 —
b 500
DrecR 39.2 6 0.9 42.2 6 3.6 35 —
b 350
DuvrB 46.7 6 6.7 42.4 6 4.6 30 —
b 400
DrecA 44.2 6 5.6 —
c 5—
d —
c
DrecB 36.5 6 0.1 —
c 5—
d —
c
DrecG 36.1 6 2.5 33.8 6 5.2
e 10 —
d 150
e
DruvB 38.3 6 6.5 37.0 6 3.9
e 10 —
d 150
e
DruvC 36.7 6 4.1 36.6 6 1.7
e 10 —
d 150
e
DpriA —
f —
c , 1.0 —
d —
c
a Complete genotypes are given in Table 1.
b Not determined.
c Mutants were not viable.
d No mutants isolated.
e Made by P1 transduction.
f Mutant grew too slowly to accurately determine doubling time.
DOI: 10.1371/journal.pbio.0030176.t002
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Inhibition of MutationE. coli, RDR is mediated by RecA ﬁlamentation on ssDNA,
created by the helicase/nuclease RecBCD, and PriA-depend-
ent replisome assembly. To test whether the RecBCD pathway
of HR is induced in the presence of ciproﬂoxacin, we
examined the DrecA, DrecB, and DrecD strains. Although the
DrecA and DrecB strains exhibited virtually wild-type viability,
both were hypersensitive to ciproﬂoxacin (see Figure 2B and
Table 2). No pre- or post-exposure mutants were observed in
either strain. To investigate whether resistant colonies were
not isolated because the gyrA(S83L) DrecA and gyrA(S83L)
DrecB double mutants are not viable, we attempted to
construct these strains by P1 transduction of the rec deletion
into a gyrA(S83L) strain. No viable double mutants could be
constructed in either case. This is consistent with previous
reports that certain mutant gyrase proteins cause increased
spontaneous fork collapse, which makes the cells dependent
on HR [42–45]. Thus, we propose that RecA/RecBC-mediated
recombination is important for cell viability in the presence
of ciproﬂoxacin both before and after the acquisition of
resistance-conferring mutations. In contrast, deletion of recD
had no effect on drug sensitivity (see Figure 2A and Table 2),
mutation rate, or mutation spectrum (Table 3). This result is
consistent with the fact that RecBC can process DSEs and
load RecA onto ssDNA in the absence of the RecD helicase
[46].
Because persistent covalently-linked topoisomerase-DNA
complexes will eventually block the progression of replication
forks, repair may occur by recombination-dependent fork
repair, which is a variant of RDR that reestablishes a
processive replication fork [22,41,47–50]. In addition to the
proteins that mediate HR (i.e., RecA and RecBC) this process
appears to require RecG and RuvABC. To test whether
recombination-dependent fork repair is induced in the
presence of ciproﬂoxacin, we examined the DrecG, DruvB,
and DruvC strains. Deletion of recG, ruvB, or ruvC did not
cause a signiﬁcant decrease in viability in the absence of
ciproﬂoxacin, but did result in high sensitivity to the drug,
although not as high as that observed with deletion of recA
and recB (see Figure 2B and Table 2). Like the DrecA and DrecB
strains, no pre- or post-exposure mutants were isolated.
However, we were able to delete recG, ruvB, and ruvC in a
gyrA(S83L) strain by P1 transduction. These double mutants
grew as well as the corresponding single mutants (see Table
2). While the double mutants each displayed signiﬁcantly
reduced MICs relative to the gyrA(S83L) single mutant (see
Table 2), they were still able to form colonies on media
containing 40 ng/ml ciproﬂoxacin. Thus, selection against
resistance-conferring mutants in the recG, ruvB, and ruvC
backgrounds does not explain the absence of resistant
colonies. These results suggest that the functions of RecG,
RuvB, and RuvC are required for viability in the presence of
ciproﬂoxacin (although less so than RecA and RecB) and also
for the acquisition of resistance-conferring mutations.
Because PriA-dependent reinitiation of DNA synthesis is
important for a variety of HR models [49,51,52], it may be
required for the repair of ciproﬂoxacin-mediated DNA
damage. Deletion of priA resulted in extreme sensitivity to
ciproﬂoxacin (MIC of less than 1 ng/ml), implying that
replication restart is essential in response to the drug (see
Figure 2B and Table 2). As with the rec and ruv strains, no
mutants were isolated before or after exposure to ciproﬂox-
acin, and as with the DrecA and DrecB strains, we were unable
to construct the gyrA(S83L) DpriA double mutant. These
results imply that replication restart is essential in response
to ciproﬂoxacin and in tolerating the resistance-conferring
gyrase mutations.
Figure 2. Survival of E. coli Mutants In Vitro
Survival on solid media containing 40 ng/ml ciproﬂoxacin of DlacZ
control and (A) NER and recombination mutants with wild-type
sensitivity, (B) recombination mutants that were hypersensitive to
ciproﬂoxacin, and (C) lexA(S119A) and inducible polymerase mutants.
DOI: 10.1371/journal.pbio.0030176.g002
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Inhibition of MutationInduction of the LexA-Repressed Polymerases Does Not
Contribute to Survival but Is Critical for the Evolution of
Ciprofloxacin Resistance In Vitro
To characterize how LexA cleavage induces resistance, we
examined the role of the three LexA-repressed polymerases,
Pol II (polB), Pol IV (dinB), and Pol V (umuD and umuC) in
survival and mutation in vitro. In every respect, the effects of
deleting a single LexA-repressed polymerase (i.e., DpolB,
DdinB, or DumuDC), or any combination of the three, were
the same as the effects of preventing LexA cleavage. First, the
pol deletion strains showed similar sensitivities to ciproﬂox-
acin as the control strain (Figure 2C and Table 2). (The DpolB,
DpolB DdinB, DpolB DumuDC, and DpolB DdinB DumuDC strains
were all slightly sensitive to ciproﬂoxacin, which is consistent
with a role for replication restart in the response to the drug,
as replication restart is thought to involve Pol II [1,41,53]).
Second, the MIC of each gyrA pol mutant was virtually
identical to that of the corresponding gyrA single mutant
( T a b l e2 ) .T h i r d ,t h ep r e - e x p o s u r em u t a t i o nr a t ea n d
spectrum of the pol deletion strains were the same as the
control; however, the post-exposure rates were markedly
reduced (Table 3). Finally, resistance in the post-exposure
mutants was acquired strictly through deletion of either
Ser83 or Ala84, and not through substitution (29 clones
sequenced; Table 3). These results suggest that it is through
the derepression of all three repressed polymerases that LexA
cleavage induces substitution mutations.
Discussion
The discovery and development of antibiotics revolution-
ized medicine, providing easy cures for previously untreat-
able diseases. However, for every signiﬁcant infectious disease
caused by bacteria, strains resistant to all available antibiotics
have been reported [54]. We are interested in understanding
how bacteria evolve resistance, and have ﬁrst focused on the
antibiotic ciproﬂoxacin. Ciproﬂoxacin and the other quino-
lones are perhaps the most important antibiotics currently
available [16], partly because of the low levels of resistance
currently observed with these newer synthetic drugs. How-
ever, clinical resistance to the quinolones is evolving at an
alarming rate due to mutations in gyrase, topoisomerase IV,
and efﬂux pumps or their regulators [1]. In this study we have
shown, in vivo, that preventing LexA cleavage renders
bacteria unable to evolve resistance to either ciproﬂoxacin
or rifampicin in a mouse thigh infection model. In vitro, the
ability of bacteria to induce mutation and evolve resistance to
ciproﬂoxacin is also dramatically reduced by rendering LexA
uncleavable. Thus, our results indicate that the mutations
that confer resistance to ciproﬂoxacin and rifampicin are not
simply the result of unavoidable errors accumulated during
genome replication, but rather are induced via the derepres-
sion of genes whose protein products act to signiﬁcantly
increase mutation rates.
In principle, part of the observed increase in mutation rate
after exposure to ciproﬂoxacin could result from selection
against resistant mutants during the pre-exposure growth in
liquid media (thus underestimating the pre-exposure muta-
tion rates). However, the impact of selection is unlikely to be
signiﬁcant, as gyrA mutations are tolerated without a
signiﬁcant increase in doubling time (Table 2). Further
evidence that the resistance-conferring mutations are in-
duced is provided by the fact that deletion or mutation of
several genes, including lexA, renders cells unable to evolve
signiﬁcant levels of resistance.
The data suggest that the increase in mutation rate is
caused by recombination pathways that are induced to repair
antibiotic-mediated DNA damage. A mechanism consistent
with our results is illustrated in Figure 3. Three recombina-
tional repair pathways appear to be involved that are
Table 3. Mutation Spectra and Rates
Relevant Genotype gyrA Mutation Spectrum Mutation Rate ([Mutants/Viable Cell/Day] 3 10
8)
Pre-Exposure Post-Exposure
Percent Base
Substitution
Percent
Codon
Deletion
Percent Base
Substitution
Percent
Codon
Deletion
Pre-Exposure Post-Exposure,
Day 5–8
Post-Exposure,
Day 9–13
DlacZ 100 (10/10) 0 (0/10) 79 (15/19) 21 (4/19) 0.090 6 0.095 1,260 6 308 1,830 6 690
DpolB 100 (8/8) 0 (0/8) 0 (0/7) 100 (7/7) 0.018 6 0.007 59 6 11 343 6 343
DdinB 100 (6/6) 0 (0/6) 0 (0/6) 100 (6/6) 0.116 6 0.176 64 6 35 468 6 270
DumuDC 100 (8/8) 0 (0/8) 0 (0/4) 100 (4/4) 0.029 6 0.004 11 6 20 516 6 447
DpolB,DdinB 100 (4/4) 0 (0/4) 0 (0/6) 100 (6/6) 0.075 6 0.039 65 6 34 57 6 99
DpolBDumuDC 100 (6/6) 0 (0/6) 0 (0/2) 100 (2/2) 0.018 6 0.001 65 6 112 74 6 129
DdinBDumuDC 100 (6/6) 0 (0/6) 0 (0/3) 100 (3/3) 0.036 6 0.020 19 6 38 62 6 125
DpolBDdinBDumuDC 100 (8/8) 0 (0/8) 0 (0/1) 100 (1/1) 0.248 6 0.317 50 6 87 No mutants
lexA(S119A) 100 (9/9) 0 (0/9) 0 (0/3) 100 (3/3) 0.016 6 0.015 7 6 14 14 6 30
DrecD 100 (8/8) 0 (0/8) 80 (8/10) 20 (2/10) 0.047 6 0.047 785 6 474 1,500 6 724
DrecF 100 (5/5) 0 (0/5) nd nd 0.307 6 0.250 302 6 11 1,640 6 291
DrecO 100 (5/5) 0 (0/5) nd nd 0.024 6 0.011 1,730 6 83 2,160 6 511
DrecR 100 (5/5) 0 (0/5) nd nd 0.086 6 0.038 2,070 6 10 1,900 6 636
DuvrB 100 (4/4) 0 (0/4) nd nd 0.112 6 0.104 927 6 85 2,430 6 1008
In parentheses is the ratio of the number of events observed to the total number mutants sequenced.
nd, not determined.
DOI: 10.1371/journal.pbio.0030176.t003
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Inhibition of Mutationdistinguished by the type of damage they repair and the type
of mutation they induce. One pathway is IR-mediated repair
of free DSBs where the protein has dissociated from the DNA
(pathway A, Figure 3). We suggest that this pathway is
responsible for the observed codon deletions. The induction
of small nucleotide deletions has been observed in bacteria
[55–57], and in eukaryotes, it has been suggested that small
deletions (including codon deletions) arise during IR after an
inhibited topoisomerase aberrantly releases free DSBs, the
ends of which are processed by exonucleases and polymerases
before being rejoined [58]. While we may have observed a
similar phenomenon in our in vitro studies, the codon
deletion mutants are unlikely to be of much clinical
signiﬁcance on their own, as they have relatively low
ciproﬂoxacin MICs (Table 2) and have never been observed
in the clinic [1,33]. Isolation of these mutants in the current
study was most likely due to the permissive drug concen-
trations employed.
In addition to IR, RDR and replication fork repair are also
induced to repair DSBs in cases where the topoisomerase has
dissociated from, or remains bound to, the DNA, respectively
(pathways B and C, Figure 3). These pathways may be more
relevant to clinical resistance as they induce the substitution
mutations ubiquitously found in clinically resistant strains. In
both pathways, the RecBCD nuclease/helicase loads at DSEs
generated (directly or indirectly) by ciproﬂoxacin and
simultaneously degrades and unwinds the duplex while
loading RecA onto the ssDNA of the nascent 39-overhang.
(For replication fork repair, RecG and RuvABC are required
to prepare the DSE [50,59,60].) RecA forms ﬁlaments that
promote strand invasion of the ssDNA into a homologous
sequence, resulting in the formation of an intermediate
known as a displacement-loop structure (D-loop). The
invading strand may then prime DNA synthesis, using the
homologous sequence as a template, ultimately restoring the
genetic information disrupted by the DSE [48]. In the case of
replication fork repair, the covalently bound topoisomerase
must still be displaced from DNA in order to reinitiate
processive synthesis. We propose that the topoisomerase is
displaced by RuvAB, which has recently been shown to
branch migrate D-loop-like structures and simultaneously
displace covalently-bound ciproﬂoxacin-topoisomerase IV
complexes [61], or perhaps by Rep or UvrD helicase, which
have both been shown to displace bound proteins from
duplex DNA [62]. Following PriA recognition and binding, a
processive replication fork is reestablished. However, with the
continued presence of ciproﬂoxacin these processes will
continue, resulting in the persistence of the RecA-ssDNA
ﬁlaments, which eventually degrade enough LexA to dere-
press the error-prone, SOS-regulated polymerases (pathway
D, Figure 3).
T h ed a t as u g g e s tt h a tt h ei nduction of substitution
mutations requires the derepression of all three SOS-
regulated polymerases, Pol II, Pol IV, and Pol V. While the
evolution of resistance to ciproﬂoxacin by substitution
mutation is to our knowledge the ﬁrst process found to
require all three of the E. coli inducible polymerases, this
observation is consistent with previous studies showing that
multiple polymerases are required for some mutations
[9,41,63,64]. It is also consistent with the two-step model of
translesion synthesis, wherein one specialized polymerase is
required for dNTP misinsertion and another for continued
synthesis (mispair extension) [9,27,65]. We propose that the
induced mutations conferring antibiotic resistance in vitro
and in vivo are the result of Pol V mispair synthesis [66,67]
and Pol IV mispair extension [10,68], while Pol II may be
required to initiate replication restart [41, 53] (after which it
may be replaced by Pol V and then Pol IV), or to ﬁx the
nascent mutation by extending the primer terminus sufﬁ-
ciently to avoid exonucleolytic proofreading upon reloading
of Pol III [69]. This process continues until mutations are
made that allow for the resumption of normal DNA synthesis.
The key signal that links the cellular response to the
antibiotic with the evolution of resistance appears to be the
RecA-ssDNA ﬁlaments that are formed to facilitate the repair
of antibiotic-mediated DNA damage. These RecA-ssDNA
ﬁlaments also induce LexA cleavage and derepression of the
mutagenic polymerases. We suggest that a similar mechanism
might also serve to induce mutation and evolution in
response to other antibiotics, or other forms of cellular
stress, where DNA damage per se is not involved. For
example, the ratio of ATP to ADP determines the level of
supercoiling in the bacterial genome [17], and both increased
and decreased levels of supercoiling inhibit replication fork
progression [70]. Thus, different stresses that perturb
metabolism (i.e., alter ATP/ADP ratios) might also alter
DNA topology and result in stalled replisomes; recombina-
tion-based rescue and RecA-ssDNA ﬁlament formation; and
the induction of mutations required to reestablish a normal
Figure 3. Proposed Response to Ciprofloxacin
In the absence of homologous sequences, free DSBs are repaired by
nuclease and polymerase-dependent IR (pathway A). In the presence
of a suitable homologous sequence, free DSBs may be repaired by
RDR (pathway B). This involves resectioning of the DNA ends by
RecBC and loading of RecA onto the ssDNA produced. These RecA-
ssDNA ﬁlaments catalyze D-loop formation and repair of the DSB.
This pathway may also contribute to the repair of replication forks
when they encounter the free DSB. Finally, replication forks that
encounter topoisomerases that are covalently-bound to the DNA are
repaired by recombination-dependent fork repair (pathway C). This
involves RecG-mediated fork regression and RuvC cleavage to
produce DSEs where RecBC mediates RecA-ssDNA ﬁlament for-
mation. These ﬁlaments catalyze strand invasion of a homologous
sequence where PriA, and possibly Pol II, help to reestablish a
processive replication fork. With sufﬁcient accumulation of DSBs and
collapsed forks, persistent RecA-ssDNA ﬁlaments induce levels of
LexA cleavage sufﬁcient to de-repress the error prone polymerases,
Pol IV and Pol V, which cooperate to induce mutations (pathway D).
Once resistance-conferring mutations are made, DSBs and collapsed
forks cease to accumulate and RecA-ﬁlaments no longer persist.
Subsequently, the cellular concentration of LexA increases, shutting
down expression of the pro-mutagenic polymerases. See text for
details.
DOI: 10.1371/journal.pbio.0030176.g003
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Inhibition of Mutationcellular environment. Interestingly, it has recently been
shown that b-lactams can induce the SOS response via a
two-component signal transduction system [71].
The traditional paradigms of DNA replication and muta-
tion suggest that resistance-conferring mutations are the
inevitable consequence of polymerase errors, and offer no
obvious means for intervention. In stark contrast, the model
described above suggests that bacteria play an active role in
t h em u t a t i o no ft h e i ro w ng e n o m e sb yi n d u c i n gt h e
production of proteins that facilitate mutation, including
Pol IV and Pol V, as has been suggested with other forms of
mutation [7–15]. In turn, this suggests that inhibition of these
proteins, or the prevention of their derepression by
inhibition of LexA cleavage, with suitably designed drugs,
might represent a fundamentally new approach to combating
the emerging threat of antibiotic-resistant bacteria. Future
efforts will focus on determining the generality of the
observations, in terms of both other pathogenic bacteria
and other antibiotics.
Materials and Methods
Bacterial strains and growth. Strains of E. coli used in this study are
listed in Table 1. Solid media was Lennox LB [72] plus 1.6% agar;
liquid media was Miller LB [72]. For selection in MG1655- and ATCC
25922-derived strains, antibiotics were used as follows: kanamycin, 30
and 50 lg/ml; spectinomycin, 100 lg/ml; and chloramphenicol, 20 lg/
ml. All bacteria were grown at 37 8C unless otherwise indicated.
Ciproﬂoxacin and rifampicin were purchased from MP Biomedicals
(Aurora, Ohio, United States). For strain construction and additional
experimental details, see Protocol S1.
A standard mouse infection model was employed [29]. Brieﬂy, 6-
wk-old, speciﬁc-pathogen-free, female CD-1 mice (weight, 23–27 g;
Harlan Sprague Dawley) were used. Mice were rendered neutropenic
(neutrophil counts less than 100/mm
3) by intraperitoneal injection
with 150 mg/kg cylcophosphamide (Mead Johnson Pharmaceuticals,
Evansville, Indiana, United States) 4 d before infection and 100 mg/kg
cyclophosphamide 24 h before infection. Previous studies have shown
that this regimen produces neutropenia in this model for 5 d [73].
Mueller-Hinton (MH) (Difco) broth cultures inoculated from freshly
plated bacteria were grown to logarithmic phase (OD580 of
approximately 0.3), and diluted 1:10 in MH broth. Thigh infections
were produced by injecting 0.1 ml volumes (approximately 10
6 cfu) of
the diluted broth cultures into halothane-anesthetized mice. Starting
2 h after infection (deﬁned as time zero), mice were administered
subcutaneous injections of either 0.5 mg/kg ciproﬂoxacin or 100 mg/
kg rifampicin every 12 h for 3 d. After 24, 48, and 72 h, both thighs
from two sacriﬁced animals were removed and homogenized. Serial
dilutions of homogenates of each thigh were plated on MH agar
(MHA) and MHA containing either 80 ng/ml ciproﬂoxacin or 128 lg/
ml rifampicin (lower limit of detection was 100 organisms/thigh).
MICs for both ciproﬂoxacin and rifampicin were determined by
standard microdilution methods of the National Committee for
Clinical Laboratory Standards. MICs prior to drug exposure for both
the LexA mutant and control strains were determined by examining
ten clones isolated from MHA plates. MICs of the post-exposure
isolates from both the LexA mutant and control strains were
determined by examining ten clones isolated from the MHA plates
at the 72-h time point.
Mutation assay. For each strain, ﬁve independent cultures were
grown for 25 h without ciproﬂoxacin. Viable cell counts in these
cultures were determined by plating serial dilutions onto permissive
media. For assaying mutation in MG1655-derived strains, 150 ll from
each culture (approximately 10
8 cells) was plated in duplicate on LB/
agar containing 40 ng/ml ciproﬂoxacin. Five additional 150 ll
aliquots from two cultures of each strain were also plated on the
same media for use in the ‘‘survival’’ assay (see below). ATCC 25922-
derived strains were assayed similarly with 12 ng/ml ciproﬂoxacin,
except cultures were concentrated approximately 3-fold before
plating to assay the same number of cells as in the MG1655
experiments. At 24 h intervals, visible colonies were counted, their
location on the plate was marked, and they were stocked at80 8C for
later use in the reconstruction assay (see below).
Survival assay. Every 24 h, in parallel with the mutation assay, all
visible colonies were excised from plates designated for assaying
survival (see above), the remaining agar was homogenized in saline,
and dilutions were plated in duplicate on LB/agar to determine the
total number of viable, ciproﬂoxacin-sensitive cells present as a
function of time, and LB/agar containing 40 ng/ml ciproﬂoxacin to
determine if any ciproﬂoxacin-resistant colonies remained after
excision. An experimental validation of this method is described in
Protocol S1 and Table S3.
Reconstruction assay. We determined whether colonies isolated
after plating on ciproﬂoxacin formed as a result of post-exposure
mutation or as a result of mutation prior to exposure to the drug.
Liquid cultures of permissive media were inoculated with ciproﬂox-
acin-resistant clones stocked during the mutation assay (see above)
and grown to saturation overnight. Cultures were diluted and plated
in duplicate on both LB/agar, to conﬁrm viability, and LB/agar
containing 40 ng/ml ciproﬂoxacin, to conﬁrm resistance. Clones that
were resistant before exposure were deﬁned as those that formed
colonies on the ciproﬂoxacin-containing media in the same number
of days in the reconstruction assay as they did in the original
mutation assay. Conversely, clones that mutated after exposure to
ciproﬂoxacin were deﬁned as those that formed colonies at least 2 d
faster in the reconstruction assay.
To further conﬁrm our assignment of the pre- and post-exposure
mutants, an alternative method was also employed. Ciproﬂoxacin-
resistant clones isolated during the mutation assay were suspended in
1 ml of 9 mg/ml NaCl. A series of dilutions was plated onto permissive
media (LB/agar) and plates were incubated at 37 8C for 24–48 h. From
each set of dilution plates, a plate was chosen that contained
approximately 50–300 colonies. This plate was replica-plated onto
permissive and nonpermissive media (LB/agar with 40 ng/ml cipro-
ﬂoxacin), and replica plates were incubated at 37 8C. Replica plates
were analyzed at 24 h intervals for the appearance of colonies (Figure
S4). At the same time, the ciproﬂoxacin-resistant clones were also
assayed using the reconstruction method described above. The two
reconstruction assays gave identical results.
Calculation of the rate at which cells become resistant to
ciproﬂoxacin (mutation rate). Mutation rate was deﬁned as the
number of ciproﬂoxacin-resistant mutants per viable cell that evolve
as a function of time. We emphasize that it reﬂects only those
mutations that both allow cells to survive and confer resistance to the
drug. The mutation rate before exposure to ciproﬂoxacin (pre-
exposure rate) was determined by ﬂuctuation analysis and applica-
tion of the p0 method [74]. The mutations after exposure to
ciproﬂoxacin (post-exposure rate) exhibited the expected Poisson
distribution [7–15] and the associated rate was therefore determined
as the ratio of colonies on a particular day to the number of cells
present at the time the cells became resistant, which we approxi-
mated as the viable cell count 2 d prior. The assumption that a colony
takes 2 d to form accounts for both the actual time required for
colony growth and the time required to turn over any residual
ciproﬂoxacin-sensitive protein, i.e., phenotypic lag. After determin-
ing the post-exposure mutation rate for each day from days 3–13,
rates were averaged over days 3–4, 5–8, and 9–13. Error bars reﬂect
standard deviation in rate determinations from at least three
independent sets of experiments.
Supporting Information
Figure S1. In Vitro Mutation Rate of ATCC 25922-Derived Strains
Mutation rate of ATCC 25922 (1), ATCC 25922-DlacZ (2), and ATCC
25922-lexA(S119A) (3). Bars represent total mutation rate (base
substitution and codon deletion).
Found at DOI: 10.1371/journal.pbio.0030176.sg001 (59 KB TIF).
Figure S2. gyrA Mutant Growth on Ciproﬂoxacin Is Not Affected by
Genetic Background
Growth of gyrA(S83L) mutant clones in the (A) DlacZ, (B) DpolB DdinB
DumuDC,a n d( C )lexA(S119A) genetic backgrounds on LB/agar
containing 40 ng/ml ciproﬂoxacin. Plates were photographed after
incubation at 37 8C for 24 h.
Found at DOI: 10.1371/journal.pbio.0030176.sg002 (945 KB TIF).
Figure S3. Stepwise Mutation Rate
Stepwise mutation rate of DlacZ, gyrA(S83L) (1) and lexA(S119A),
gyrA(S83L) (2) to 650 ng/ml ciproﬂoxacin.
Found at DOI: 10.1371/journal.pbio.0030176.sg003 (48 KB TIF).
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Inhibition of MutationFigure S4. Reconstruction of Mutants by Replica Plating
Re-growth of eight DlacZ ciproﬂoxacin-resistant colonies isolated
during the mutation assay on (A) Day 5, (B and C) Day 6, (D and E)
Day 7, (F) Day 8, (G) Day 9, and (H) Day 10, 48 h after replica-plating
onto LB/agar (left) and LB/agar containing 40 ng/ml ciproﬂoxacin
(right). This reconstruction method demonstrates that all of the cells
from a colony isolated during the mutation assay are ciproﬂoxacin
resistant. See Materials and Methods for details.
Found at DOI: 10.1371/journal.pbio.0030176.sg004 (2.4 MB TIF).
Protocol S1. Supplementary Methods
Found at DOI: 10.1371/journal.pbio.0030176.sd001 (195 KB DOC).
Table S1. Effect of Different Ciproﬂoxacin-Resistance Mutations
Found at DOI: 10.1371/journal.pbio.0030176.st001 (28 KB DOC).
Table S2. Primers Used in This Work
Found at DOI: 10.1371/journal.pbio.0030176.st002 (72 KB DOC).
Table S3. Validation of Survival Assay
Found at DOI: 10.1371/journal.pbio.0030176.st003 (42 KB DOC).
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